

Outlook Therapeutics, Inc. Logo

## Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

August 4, 2022

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [Russ Trenary, President and Chief Executive Officer](#) of Outlook Therapeutics, will present at the [H.C. Wainwright 2<sup>nd</sup> Annual Ophthalmology Conference](#) being held virtually on Wednesday, August 17.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A [video webcast](#) of the presentation will be accessible for viewing on-demand beginning on Wednesday, August 17, 2022, at 7:00 AM ET for those registered for the event and will be available on the [Events](#) page in the [Investors](#) section of the Company's website ( [outlooktherapeutics.com](#)). The webcast replay will be archived for 90 days following the event.

### About Outlook Therapeutics, Inc.

Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit [www.outlooktherapeutics.com](#).

### CONTACTS:

#### Media Inquiries:

Harriet Ullman  
Vice President  
LaVoie Health Science  
T: 617-669-3082  
[hullman@lavoiehealthscience.com](mailto:hullman@lavoiehealthscience.com)

#### Investor Inquiries:

Jenene Thomas  
Chief Executive Officer  
JTC Team, LLC  
T: 833.475.8247  
[OTLK@jtcir.com](mailto:OTLK@jtcir.com)



Source: Outlook Therapeutics, Inc.